April - June- Total revenue of
SEK 3,211 M (3 070), 5 per cent growth and 14 per cent at CER -
EBITA1 was
SEK 922 M (1,018), with an EBITA margin1 of 29 per cent (33) - Earnings per share (EPS) before dilution of
SEK 0.91 (0.96) -
Haematology sales were
SEK 2,125 M (2,037), 12 per cent growth at CER -
Sales for Elocta® were
SEK 1,005 M (1,040), 2 per cent growth at CER -
Sales for Alprolix® were
SEK 438 M (363), 27 per cent growth at CER -
Doptelet® grew by 42 per cent at CER to
SEK 230 M -
Immunology sales were
SEK 752 M (714), Gamifant® grew by 46 per cent at CER to SEK 168 M (132) -
Cash flow from operating activities of
SEK 1,393 M (1,942)
January - June
- Total revenue of
SEK 6,872 M (7,709), -11 per cent and -2 per cent at CER -
EBITA1 was
SEK 2,406 M (3,191), with an EBITA margin1 of 35 percent (41) - EPS before dilution of
SEK 3.27 (4.98) -
Haematology sales were
SEK 4,003 M (4,431), -3 per cent at CER -
Sales for Elocta were
SEK 1,861 M (2,399), -18 per cent at CER -
Sales for Alprolix were
SEK 851 M (851), 6 per cent growth at CER -
Doptelet grew by 88 per cent at CER to
SEK 411 M -
Immunology sales were
SEK 2,305 M (2,514), Gamifant grew by 47 per cent at CER toSEK 301 M (236) -
Cash flow from operating activities of
SEK 3,092 (3,828)
Significant events after the reporting period
- In July, Kineret® was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure
Outlook 2021 - unchanged
- Revenue for the full-year 2021 is expected to be in the range of
SEK 14,000-15,000 M -
EBITA margin is expected to be in the range of 30-35 per cent of revenue
"We ended the second quarter on a positive note and are back to double-digit growth. Our figures are still impacted by the COVID-19 pandemic and its related restrictions and lock-downs, but as restrictions have eased, we have started to see improved market conditions. During the quarter, we advanced the R&D portfolio such as pegcetacoplan and efanesoctocog alfa, as well as anakinra (Kineret) for the treatment of COVID-19 pneumonia."
Financial Summary
Q2 | Q2 | H1 | H1 | Full-year | |||
SEK M | 2021 | 2020 | Change | 2021 | 2020 | Change | 2020 |
Total revenue | 3,211 | 3,070 | 5% | 6,872 | 7,709 | -11% | 15,261 |
Gross profit | 2,428 | 2,381 | 2% | 5,363 | 5,979 | -10% | 12,036 |
Gross margin1 | 76% | 78% | 78% | 78% | 79% | ||
EBITA1 | 922 | 1,018 | -9% | 2,406 | 3,191 | -25% | 6,700 |
EBITA adjusted1,2 | 922 | 1,018 | -9% | 2,406 | 3,191 | -25% | 6,301 |
EBITA margin1 | 29% | 33% | 35% | 41% | 44% | ||
EBITA margin adjusted1,2 | 29% | 33% | 35% | 41% | 41% | ||
Profit for the period | 268 | 283 | -5% | 964 | 1,465 | -34% | 3,245 |
Earnings per share, before dilution, SEK | 0.91 | 0.96 | -5% | 3.27 | 4.98 | -34% | 11.01 |
Earnings per share, before dilution, SEK adjusted1,2,3 | 0.91 | 0.96 | -5% | 3.27 | 4.98 | -34% | 9.66 |
1Alternative Performance Measures (APMs). | |||||||
2 EBITA 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of | |||||||
3EPS full-year 2020 excluding the reversal of the CVR liability of |
Telephone conference
Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, today at 13:00 CEST. The event will be hosted by Sobi's CEO and President,
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 566 426 92 (Direct)
US: +1 631 913 1422 PIN: 83892913#
Click here to go to the live webcast
After the live event the webcast will be available on-demand via the same link.
---
About Sobi(TM)
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across
This information is information that
For more information, please contact:
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 767 248 830
maria.kruse@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-report-for-the-second-quarter-2021,c3387674
https://mb.cision.com/Main/14266/3387674/1446955.pdf
(c) 2021 Cision. All rights reserved., source